Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Currie Mark G reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Mark G. Currie received a grant of 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost to him as part of director compensation.
According to the company’s non-employee director compensation policy, this restricted stock vests in full on the date immediately before the next year’s annual meeting of stockholders. After this award, Currie directly holds 676,900 shares of Ironwood common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Currie Mark G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 63,481 | $0.00 | -- |
Holdings After Transaction:
Class A Common Stock — 676,900 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Restricted stock grant: 63,481 shares
Grant price per share: $0.00 per share
Total shares after grant: 676,900 shares
3 metrics
Restricted stock grant
63,481 shares
Class A Common Stock awarded to director Mark G. Currie
Grant price per share
$0.00 per share
Stated transaction price for restricted stock award
Total shares after grant
676,900 shares
Currie’s direct holdings following the transaction
Key Terms
restricted stock, Second Amended and Restated Non-employee Director Compensation Policy, annual meeting of stockholders
3 terms
restricted stock financial
"The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Second Amended and Restated Non-employee Director Compensation Policy financial
"granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024"
annual meeting of stockholders financial
"vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year"
FAQ
What did Ironwood Pharmaceuticals (IRWD) director Mark G. Currie report in this Form 4?
Director Mark G. Currie reported receiving 63,481 shares of Ironwood Class A common stock as restricted stock. The award was granted at no cash cost under the company’s non-employee director compensation policy and is part of his board compensation package.
What are the vesting terms of Mark G. Currie’s new Ironwood restricted stock?
The 63,481 restricted shares granted to Mark G. Currie vest in full on the date immediately preceding Ironwood’s annual meeting of stockholders for the next calendar year. Until vesting, the shares are subject to the restricted stock conditions described in the company’s policy.
What compensation policy governed Mark G. Currie’s Ironwood restricted stock award?
The award was granted under Ironwood’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. This policy outlines how non-employee directors are compensated, including equity grants such as the restricted stock disclosed here.